Gressner, Olav A.

Publishing since 2007 (Baby)

Has published 18 publications in 4 years

Number of publications published per year by Gressner, Olav A.. (Source : PubMed)

Distribution of publications types for Gressner, Olav A.. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Grünhage F, Nattermann J, Gressner OA, Wasmuth HE, Hellerbrand C, Sauerbruch T, Spengler U, Lammert F. Lower copy numbers of the chemokine CCL3L1 gene in patients with chronic hepatitis C.  J. Hepatol.  2010;52;2  
•  Kovalenko E, Tacke F, Gressner OA, Zimmermann HW, Lahme B, Janetzko A, Wiederholt T, Berg T, Müller T, Trautwein C, Gressner AM, Weiskirchen R. Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis.  J. Viral Hepat.  2009;16;9  
•  Gressner OA. Less Smad2 is good for you! A scientific update on coffee's liver benefits.  Hepatology  2009;50;3  
•  Gressner OA, Gao C, Siluschek M, Kim P, Gressner AM. Inverse association between serum concentrations of actin-free vitamin D-binding protein and the histopathological extent of fibrogenic liver disease or hepatocellular carcinoma.  Eur J Gastroenterol Hepatol  2009;21;9  
•  Gressner OA, Lahme B, Siluschek M, Gressner AM. Identification of paraxanthine as the most potent caffeine-derived inhibitor of connective tissue growth factor expression in liver parenchymal cells.  Liver Int.  2009;29;6  
•  Gressner OA, Lahme B, Siluschek M, Rehbein K, Weiskirchen R, Gressner AM. Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor beta actions in hepatocytes--but without modulating bone morphogenetic protein 7 signaling.  Hepatology  2009;49;6  
•  Gressner AM, Gao CF, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey.  World J. Gastroenterol.  2009;15;20  
•  Gressner OA, Gao C, Rehbein K, Lahme B, Siluschek M, Berg T, Müller T, Gressner AM. Elevated concentrations of 15-deoxy-Delta12,14-prostaglandin J2 in chronic liver disease propose therapeutic trials with peroxisome proliferator activated receptor gamma-inducing drugs.  Liver Int.  2009;29;5  
•  Gressner OA, Siluschek M, Lahme B, Gressner AM. Intraperitoneal application of caffeine prevents D-galactosamine-induced hepatic expression of connective tissue growth factor (CTGF/CCN2) in the rat.  J. Hepatol.  2009;50;5  
•  Weber S, Gressner OA, Hall R, Grünhage F, Lammert F. Genetic determinants in hepatic fibrosis: from experimental models to fibrogenic gene signatures in humans.  Clin Liver Dis  2008;12;4  

[ See timeline ] [ See all publications ]